A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Multiple Escalating Oral Doses Of PF-04620110 In Otherwise Healthy Overweight And Obese Adult Subjects
| Registry | NCT00959426 |
|---|
| Status | Completed |
|---|
| Phase | Phase 1 |
|---|
| Study type | Interventional; randomized, parallel, masking: triple, treatment |
|---|
| Enrollment | 71 (Actual) |
|---|
| Sponsor | Pfizer (Industry); collaborators: Bristol-Myers Squibb |
|---|
| Conditions | Obesity, Overweight, Healthy |
|---|
| Interventions | PF-04620110, Placebo (Drug) |
|---|
| Dates | start 2009-08-01, primary completion 2010-05-01, completion 2010-05-01, first posted 2009-08-14, last updated 2010-06-07 |
|---|
| Locations | 1 site in United States |
|---|
Related Papers Related Patents Related Grants Related Experts
All trials for Obesity All trials for Overweight All trials of PF-04620110 All trials of Placebo
-Summary
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics, of multiple oral doses of PF-04620110.
Expand all sections · Collapse all
+Arms and interventions
| Arm | Type | Interventions | Description |
|---|
| PF-04620110 | Experimental | Drug: PF-04620110 | |
| Placebo Comparator | Placebo comparator | Drug: Placebo | |
- PF-04620110 (Drug): Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.
- Placebo (Drug): Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
+Outcome measures
Primary outcomes
- To assess safety and tolerability of PF-04620110 will be assessed by physical examinations, adverse event monitoring, 12-lead ECGs, vital sign, andc linical safety laboratory measurements. [Baseline to 2 weeks]
- To characterize the PK of PF-04620110 following multiple oral doses in otherwise healthy overweight and obese subjects. [Baseline to 2 weeks]
- To characterize the effect of PF-04620110 on postprandial lipid metabolism measures. [Baseline to 2 weeks]
Secondary outcomes
- To examine additional pharmacodynamic markers in response to multiple oral doses of PF-04620110. [Day -1 and Day 14]
- Secondary Pharmacodynamic Endpoints in response to a liquid meal test [Day -1 and Day 14]
- Triglyceride excursions [Day -1, Day 1, and Day 14]
- Glucose, insulin, and C-peptide excursions [Day -1 and Day 14]
- Gut hormone excursions- including active GLP-1, total amide GLP-1, ghrelin, GIP, and PYY [Day -1 and Day 14]
- Additional Secondary Pharmacodynamic Endpoint: Fasting adiponectin [Day -1 and Day 14]
+Eligibility
Sex: All, ages: 18 Years to 55 Years, accepts healthy volunteers
Inclusion Criteria:
* Healthy male and/or female subjects between the ages of 18 and 55 years
* Body Mass Index (BMI) of 26.5 to 35.5 kg/m2; and a total body weight >50 kg (110 lbs).
Exclusion Criteria:
* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at screening.
+Locations (1)
| Facility | City | Country | Status |
|---|
| Pfizer Investigational Site | New Haven, Connecticut | United States | |
+Publications
- Results publication: Amin NB, Saxena AR, Somayaji V, Dullea R. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology. Clin Ther. 2023 Jan;45(1):55-70. doi: 10.1016/j.clinthera.2022.12.008. Epub 2023 Jan 21. PMID 36690550
+Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer